Contractor
GENENTECH USA, INC
- UEI
- SA85BMHCTXK5
- Parent UEI
- WJHDT127L353
- Resolved by
- uei
- Confidence
- 1.000
Active from Sep 11, 2023 to Sep 15, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 36F79723D0219 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD | Department of Veterans Affairs | — | Sep 11, 2023 | — |
| 36E79724D0001 NEW AWARD FOR RANIBIZUMAB (LUCENTIS) SYRINGES WITH GENENTECH USA, INC. PERIOD OF PERFORMANCE IS 12/23/23 TO 12/22/24 WITH FOUR ONE-YEAR OPTIONS. | Department of Veterans Affairs | — | Oct 23, 2023 | — |
| 36E79723A0022 BPA FOR EVRYSDI | Department of Veterans Affairs | — | Sep 21, 2023 | — |
| 75A50325F80036 PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS | Department of Health and Human Services | CA | Sep 26, 2025 | $74,970,000 |
| SPE2D021D0005 4610074752! | Department of Defense | — | May 6, 2026 | — |
| SPE2D326F025W 4571520559!TNKASE 50 MG KITS | Department of Defense | CA | Apr 15, 2026 | $5,803 |
| 75A50325F80003 EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI TERMINATION FOR CONVENIENCE AGREEMENT AND CLOSEOUT MODIFICATION. | Department of Health and Human Services | CA | Mar 27, 2026 | $45,106,864 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier SA85BMHCTXK5, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Sep 24, 2026.